KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for AbbVie (ABBV) over the last 15 years, with Q3 2025 value amounting to $5.6 billion.

  • AbbVie's Cash & Equivalents fell 2243.35% to $5.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 billion, marking a year-over-year decrease of 2243.35%. This contributed to the annual value of $5.5 billion for FY2024, which is 5689.09% down from last year.
  • Latest data reveals that AbbVie reported Cash & Equivalents of $5.6 billion as of Q3 2025, which was down 2243.35% from $6.5 billion recorded in Q2 2025.
  • AbbVie's Cash & Equivalents' 5-year high stood at $18.1 billion during Q1 2024, with a 5-year trough of $5.2 billion in Q1 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $8.8 billion (2023), whereas its average is $9.4 billion.
  • Per our database at Business Quant, AbbVie's Cash & Equivalents plummeted by 7628.94% in 2021 and then surged by 16921.47% in 2024.
  • Over the past 5 years, AbbVie's Cash & Equivalents (Quarter) stood at $9.7 billion in 2021, then decreased by 5.59% to $9.2 billion in 2022, then surged by 39.27% to $12.8 billion in 2023, then plummeted by 56.89% to $5.5 billion in 2024, then grew by 1.9% to $5.6 billion in 2025.
  • Its Cash & Equivalents stands at $5.6 billion for Q3 2025, versus $6.5 billion for Q2 2025 and $5.2 billion for Q1 2025.